Keyword: Ampyra

Acorda has moved its entire salesforce over from Ampyra to new launch Inbrija. But it’s not relying solely on that team to get the ball rolling.

After losing a last-ditch court battle against Ampyra generics, Acorda now faces an FDA delay on its new Parkinson's drug Inbrija.

Acorda faces the prospect of generic competition on its primary revenue source, Ampyra, after an appeals court's decision.

Late last month, a court refused to block copies of Acorda’s Ampyra. So the New York drugmaker took matters into its own hands.

Even if Acorda loses its upcoming appeal on Ampyra's patents, its sales force won’t have to worry, CEO Ron Cohen says.

After Acorda lost a key patent fight, putting its $493 million drug Ampyra in danger, a hedge fund is pushing the biotech to sell out.

Novartis loses Gilenya patent appeal, clearing way for early copies of the $3 billion multiple sclerosis med.

Acorda Therapeutics plans to appeal a court’s recent decision to nix four of its five Ampyra patents. In the meantime, it’s preparing for the worst.

Acorda Therapeutics’ IP protection on Ampyra may have held up against an administrative patent challenge, but it didn't do the same in court.